Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 10/20 | 0.75 |
| ▸ | DHFR | P00374 | 2/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 2/20 | 0.34 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12128866 | 0.87 | APP (0.81) | APPDHFR | |
| SCHEMBL12129574 | 0.86 | APP (1.00) | APPDHFR | |
| SCHEMBL21089220 | 0.85 | APP (0.75) | APPCYP3A4CYP2D6 | |
| SCHEMBL12129630 | 0.76 | APP (0.77) | APPSLC6A4SLC6A2 | |
| SCHEMBL21089104 | 0.75 | APP (0.60) | APPDHFRCYP3A4RAPGEF4 | |
| SCHEMBL12128851 | 0.73 | APP (0.80) | APPSLC6A4 | |
| SCHEMBL12129560 | 0.72 | APP (1.00) | APP | |
| SCHEMBL12285936 | 0.72 | APP (0.74) | APPCYP3A4CYP2D6 | |
| SCHEMBL12129023 | 0.72 | APP (0.46) | APPDHFRRAPGEF4 | |
| SCHEMBL12128842 | 0.70 | APP (0.59) | APPCYP3A4CYP2D6CYP2C19RAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158242-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins | AC IMMUNE SA (CH) | 2016-06-09 | — | — | US | disclosed |
| US-20160158242-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins | AC IMMUNE SA (CH) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158242-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins | APP, PSEN1, PSEN2 | APP 1/4885DHFR 4024/4885CCR2 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.